WHO ICTRP trial
A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy…
EUCTR2004-002069-19-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2004-002069-19-GB |
|---|---|
| Public title | A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Refractory Partial Seizures |
| Scientific title | A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Refractory Partial Seizures |
| Primary sponsor | Janssen-Cilag International NV |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Spain;Belgium;United Kingdom |
| Conditions | Refractory partial epilepsy |
| Interventions | Product Name: RWJ-333369 100mg tablet Product Code: 333369-000-C-019, F003 Pharmaceutical Form: Tablet INN or Proposed INN: RWJ-333369 Current Sponsor code: RWJ-333369 Concentration unit: mg milligram(s) Concentration type: equal… |
| Registration date | Oct 2, 2005 |
| Target size | 500 |
| Secondary IDs | 333369-EPY-2003 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: